Through the blend of polymer science and capsule engineering, Lonza has developed a line of functional capsules that provides the industry with a viable alternative to achieve enteric protection and delayed release without functional (enteric) coating.
Vcaps® Enteric capsule technology simplifies drug enteric delivery implementation from early-stage development to commercial manufacturing. The pharmaceutical grades of cellulosic derivatives used in Vcaps® Enteric capsules have extensive market precedence for use in providing enteric protection. Vcaps® Enteric capsules have been evaluated in-vitro and in-vivo across a number of compounds, which has proven full compliance with relevant European, Japanese and US Pharmacopeia monographs.
Vcaps® Enteric capsules have a number of potential applications in terms of functionality, use in product development tools, and as branding and intellectual property considerations.
As a proprietary technology – and a viable alternative to enteric coating in the pharmaceutical industry – our intrinsically enteric capsule technologies offer potential product differentiation, life cycle management, and intellectual property opportunities.
Vcaps® Enteric capsules can be utilized to greatly simplify and accelerate prototype development and rapid in-vivo testing of products requiring targeted delivery to the upper GI tract:
By removing the need for enteric coating, intrinsically enteric capsule technologies also offer tremendous potential in early-stage product development, and can be utilized to greatly simplify formulation and process development, as well as scale-up and validation. Independent analysis has indicated that more than nine months of savings in Phase III readiness may be achievable by eliminating development, scale-up and validation steps associated with enteric coating (H2 Pharma Consulting, 2014).